Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-11-10 07:00 |
Cytos Biotechnology Ltd holds a Bondholders' meeting today. Trading of Cytos sh…
|
English | 6.8 KB | ||
| 2011-10-20 19:21 |
Cytos Biotechnology Ltd announces Q3 Financial Results and convenes a Bondholde…
|
English | 11.8 KB | ||
| 2011-08-29 07:00 |
Cytos Biotechnology Ltd confirms strategic and organizational changes with the …
|
English | 8.1 KB | ||
| 2011-08-17 07:00 |
Cytos Biotechnology Ltd announces strategic and organizational changes with the…
|
English | 10.7 KB | ||
| 2011-07-28 07:00 |
Cytos Biotechnology Second Quarter Report 2011
|
English | 9.9 KB | ||
| 2011-04-28 07:00 |
Cytos Biotechnology First Quarter Report 2011
|
English | 8.4 KB | ||
| 2011-03-31 07:00 |
United States Army and Cytos Biotechnology Collaborate on Malaria Vaccines Rese…
|
English | 8.5 KB | ||
| 2011-02-21 07:00 |
Cytos Biotechnology receives EU funding to work on novel vaccine approaches for…
|
English | 7.4 KB | ||
| 2011-02-17 07:00 |
Cytos Biotechnology Ltd announces full year 2010 financial results and major de…
|
English | 3.7 KB | ||
| 2011-02-10 07:00 |
Cytos Biotechnology Presents Latest Data on the Mechanism of Action of QbG10 fo…
|
English | 8.1 KB | ||
| 2010-12-16 02:00 |
A*STAR and Cytos extend Influenza Vaccine Collaboration to Supply of Clinical T…
|
English | 10.2 KB | ||
| 2010-12-09 07:00 |
Cytos Biotechnology, A*STAR and INRS present new flu vaccine data at the World …
|
English | 9.0 KB | ||
| 2010-11-05 07:00 |
New clinical study started with the nicotine vaccine NIC002
|
English | 6.9 KB | ||
| 2010-10-28 07:00 |
Cytos Biotechnology Third Quarter Report 2010
|
English | 3.6 KB | ||
| 2010-10-21 07:00 |
National Institutes of Health, SAIC, and Cytos Biotechnology Collaborate on Mal…
|
English | 6.8 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
